Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms

被引：7

作者：

Haslam, Karl ^{[1
]}

Molloy, Karen M. ^{[1
]}

Conneally, Eibhlin ^{[2
]}

Langabeer, Stephen E. ^{[1
]}

机构：

[1] St James Hosp, Cent Pathol Lab, Dublin 8, Ireland

[2] St James Hosp, Dept Haematol, Dublin 8, Ireland

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2014年 / 52卷 / 03期

关键词：

allogeneic hematopoietic stem cell transplantation; JAK2; V617F; myeloproliferative neoplasms (MPN); MUTATION; MYELOFIBROSIS; LYMPHOCYTE;

D O I：

10.1515/cclm-2013-0768

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：E29 / E31

页数：3

共 10 条

[1] Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis [J].

Alchalby, Haefaa ;

Badbaran, Anita ;

Zabelina, Tatjana ;

Kobbe, Guido ;

Hahn, Joachim ;

Wolff, Daniel ;

Bornhaeuser, Martin ;

Thiede, Christian ;

Baurmann, Herrad ;

Bethge, Wolfgang ;

Hildebrandt, York ;

Bacher, Ulrike ;

Fehse, Boris ;

Zander, Axel R. ;

Kroeger, Nicolaus .

BLOOD, 2010, 116 (18) :3572-3581

[2] Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study [J].

Jovanovic, J. V. ;

Ivey, A. ;

Vannucchi, A. M. ;

Lippert, E. ;

Leibundgut, E. Oppliger ;

Cassinat, B. ;

Pallisgaard, N. ;

Maroc, N. ;

Hermouet, S. ;

Nickless, G. ;

Guglielmelli, P. ;

van der Reijden, B. A. ;

Jansen, J. H. ;

Alpermann, T. ;

Schnittger, S. ;

Bench, A. ;

Tobal, K. ;

Wilkins, B. ;

Cuthill, K. ;

McLornan, D. ;

Yeoman, K. ;

Akiki, S. ;

Bryon, J. ;

Jeffries, S. ;

Jones, A. ;

Percy, M. J. ;

Schwemmers, S. ;

Gruender, A. ;

Kelley, T. W. ;

Reading, S. ;

Pancrazzi, A. ;

McMullin, M. F. ;

Pahl, H. L. ;

Cross, N. C. P. ;

Harrison, C. N. ;

Prchal, J. T. ;

Chomienne, C. ;

Kiladjian, J. J. ;

Barbui, T. ;

Grimwade, D. .

LEUKEMIA, 2013, 27 (10) :2032-2039

[3] Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].

Kroeger, Nicolaus ;

Holler, Ernst ;

Kobbe, Guido ;

Bornhaeuser, Martin ;

Schwerdtfeger, Rainer ;

Baurmann, Herrad ;

Nagler, Arnon ;

Bethge, Wolfgang ;

Stelljes, Matthias ;

Uharek, Lutz ;

Wandt, Hannes ;

Burchert, Andreas ;

Corradini, Paolo ;

Schubert, Joerg ;

Kaufmann, Martin ;

Dreger, Peter ;

Wulf, Gerald G. ;

Einsele, Hermann ;

Zabelina, Tatjana ;

Kvasnicka, Hans Michael ;

Thiele, Juergen ;

Brand, Ronald ;

Zander, Axel R. ;

Niederwieser, Dietger ;

de Witte, Theo M. .

BLOOD, 2009, 114 (26) :5264-5270

[4] JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation [J].

Kroeger, Nicolaus ;

Alchalby, Haefaa ;

Klyuchnikov, Evgeny ;

Badbaran, Anita ;

Hildebrandt, York ;

Ayuk, Francis ;

Bacher, Ulrike ;

Bock, Oliver ;

Kvasnicka, Michael ;

Fehse, Boris ;

Zander, Axel .

BLOOD, 2009, 113 (08) :1866-1868

[5] JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse [J].

Lange, Thoralf ;

Edelmann, Anja ;

Siebolts, Udo ;

Krahl, Rainer ;

Nehring, Claudia ;

Jakel, Nadja ;

Cross, Michael ;

Maier, Jacqueline ;

Niederwieser, Dietger ;

Wickenhauser, Claudia .

HAEMATOLOGICA, 2013, 98 (05) :722-728

[6] The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders [J].

Larsen, Thomas Stauffer ;

Christensen, Jacob Haaber ;

Hasselbalch, Hans Carl ;

Pallisgaard, Niels .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (05) :745-751

[7] The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation [J].

Lion, T. ;

Watzinger, F. ;

Preuner, S. ;

Kreyenberg, H. ;

Tilanus, M. ;

de Weger, R. ;

van Loon, J. ;

de Vries, L. ;

Cave, H. ;

Acquaviva, C. ;

Lawler, M. ;

Crampe, M. ;

Serra, A. ;

Saglio, B. ;

Colnaghi, F. ;

Biondi, A. ;

van Dongen, J. J. M. ;

van der Burg, M. ;

Gonzalez, M. ;

Alcoceba, M. ;

Barbany, G. ;

Hermanson, M. ;

Roosnek, E. ;

Steward, C. ;

Harvey, J. ;

Frommlet, F. ;

Bader, P. .

LEUKEMIA, 2012, 26 (08) :1821-1828

[8] Hemopoietic chimerism following stem cell transplantation [J].

McCann, SR ;

Crampe, M ;

Molloy, K ;

Lawler, M .

TRANSFUSION AND APHERESIS SCIENCE, 2005, 32 (01) :55-61

[9] Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation [J].

Steckel, Nina K. ;

Koldehoff, Michael ;

Ditschkowski, Markus ;

Beelen, Dietrich W. ;

Elmaagacli, Ahmet H. .

TRANSPLANTATION, 2007, 83 (11) :1518-1520

[10] Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies [J].

Tefferi, Ayalew ;

Vainchenker, William .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :573-582

← 1 →